Breathing Life into Flatlined U.S. Government Funding for Tuberculosis Research: FY 2017–2020 Allocations and Recommendations
June 2016 – This policy brief provides an overview of investments made by the U.S. government and explains how increasing TB R&D funding can catalyze the development of better vaccines, diagnostics, and treatments for TB. It is built upon resource tracking and reporting done by Treatment Action Group (TAG), and it recommends areas in which investments will not only fill research gaps but also provide clarity in the vision proposed by the National Action Plan and prevent the rising threat of multidrug-resistant TB (MDR-TB).
Research Toward a Cure
June 6, 2016 – A listing of clinical trials and observational studies related to the research effort to cure HIV infection.
New and Updated HCV Treatment Fact Sheets Now Online
May 31, 2016 – A new fact sheet on Zepatier, and updated fact sheets on Solvaldi, Harvoni, Viekira Pak, and Daklinza now available for download.
An Open Letter to Senator Sanders Challenging the Characterization of Meeting with HIV/AIDS Activists
May 27, 2016 – Dear Senator Sanders: We are grateful that you took time to sit with us this week to discuss a broad range of issues related to the fight against HIV/AIDS. Our group represents a larger coalition of over 70 organizations and advocates from across the country who hope to use this opportunity to push forward the national conversation, which is sorely missing, about HIV/AIDS. While we were optimistic following what we felt was a productive meeting, our optimism quickly turned to disappointment when your campaign issued a news release misrepresenting the meeting with HIV/AIDS leadership entitled “Sanders Backs California Ballot Initiative to Rein in Drug Prices at Meeting with HIV/AIDS Advocates.”
Hepatitis C: No More Treatment Rationing; Universal Access to Generic Medicines Everywhere!
April 16, 2016, Barcelona – People with hepatitis C virus (HCV) and their allies from Spain and around the world have gathered at the International Liver Congress to protest the outrageous price of life-saving HCV medicines. They are pushing for generic competition to bring down the price of HCV treatment and ensure universal access.
TAGline Spring 2016
NEWS ON THE FIGHT TO END HIV/AIDS, VIRAL HEPATITIS, AND TUBERCULOSIS
- Fair Pricing: Reclaiming Drugs for the Common Good
By Tim Horn
- Greed and the Necessity for Regulation
The story of U.S. drug pricing run amok isn’t just about corporate arrogance and avarice—it is also about government permissiveness and inaction
By Tim Horn, Erica Lessem, and Kenyon Farrow
- PrEP Pricing Problems
A number of barriers to pre-exposure prophylaxis (PrEP) uptake, use, and adherence have been identified—cost shouldn’t be one of them
By James Krellenstein and Jeremiah Johnson
- The Low Cost of Universal Access
Generic treatments for HIV, viral hepatitis, and cancer can be affordably—and profitably—mass-produced for broad, unobstructed availability
By Tracy Swan
AIDS Advocates from Across the U.S. Call upon Presidential Candidates to Make Ending the Epidemic a Priority
March 15, 2016 – Secretary Clinton's mischaracterization of the Reagan Administration on Friday, March 11, sparked nationwide upset from HIV/AIDS advocates, service providers, people living with HIV, and loved ones of those lost to the epidemic. But it also has created an opportunity to bring HIV/AIDS to the forefront of the conversation during this campaign season.
HIV Community Letter to Hillary for America
March 14, 2016 – Dear Secretary Clinton: We write to you in the sincere hope that we can work together to transform the pain caused by your March 11th mischaracterization of the Reagans’ role in the AIDS crisis into an urgently needed public discussion of a plan to end the United States HIV epidemic by the year 2025.
TAG Welcomes Delamanid’s Inclusion in the Stop TB Partnership’s Global Drug Facility
February 24, 2016 – Treatment Action Group (TAG) congratulates the Stop TB Partnership and Otsuka Pharmaceutical for arranging for the inclusion of delamanid, an important new medicine for treating some cases of multidrug-resistant tuberculosis (MDR-TB), in the Global Drug Facility (GDF). TB is the leading infectious cause of death globally, and new medicines to treat drug-resistant strains of TB are urgently needed. TAG commends the GDF and the Stop TB Partnership for their leadership in securing access to delamanid with minimal barriers and at a single flat price for all Global Fund-eligible countries.
Pre-CROI Community HIV Cure Research Workshop 2016
February 22, 2016 – On Sunday February 21, 2016, in Boston, the AIDS Treatment Activists Coalition, AVAC, European AIDS Treatment Group, Project Inform, and TAG co-sponsored a community workshop on HIV cure research. The workshop has become an annual event that takes place immediately prior to the Conference on Retroviruses and Opportunistic Infections (CROI). Slide presentations are available at the link above, and there is coverage of workshop on the EATG at CROI 2016 Facebook page.
Treatment Action Group Hails Governor Cuomo’s Proposed Legislation Allowing Minors to Maintain Confidentiality When Obtaining HIV Treatment or Preventive Therapy
February 11, 2016 – “Governor Cuomo continues to provide globally unprecedented leadership with New York State's plan to end AIDS as an epidemic by the year 2020,” said Treatment Action Group executive director Mark Harrington. “With today's announcement that he will submit legislation allowing minors to consent to receive antiretroviral therapy (ART) or pre-exposure prophylaxis (PrEP) to treat or prevent HIV infection, New York State moves closer to achieving an AIDS-free generation in this decade. Treatment Action Group salutes the governor's sustained leadership in these efforts and calls on state legislators to rapidly and unanimously pass this lifesaving, infection-averting legislation to end AIDS and HIV acquisition among our state's youth."
MapCrowd: An Online Data Collection Platform for Hepatitis C information
February 8, 2016 – Médecins du Monde (MdM) and Treatment Action Group (TAG) are pleased to announce the launch of mapCrowd (www.mapCrowd.org), an innovative online resource and data collection platform for gathering and sharing hepatitis C information.
TAG’s Response to the U.S. Action Plan for Combating Multidrug-Resistant Tuberculosis
January 7, 2016 – Treatment Action Group (TAG) welcomes the release of the Obama Administration’s National Action Plan for Combating Multidrug-Resistant Tuberculosis. Strengthening the domestic and global and research efforts to address multidrug-resistant tuberculosis (MDR-TB) are critical to ending the suffering this preventable, curable disease needlessly causes. However, the targets set forth in this plan are not ambitious enough to effectively stop the spread of MDR-TB. The Administration and Congress must appropriate funding levels to ensure that the U.S. can effectively address MDR-TB.
HCV Fact Sheets in English and en Español
December 14, 2015 – This set of fact sheets include information on adherence to treatment, HCV diagnostics, and currently approved treatments (Sovaldi, Olysio, Viekira Pak and Technivie, Harvoni, Daklinza, and ribavirin).
TAG’S PROGRESS ON THE FIGHT TO END HIV/AIDS, VIRAL HEPATITIS, AND TUBERCULOSIS
December 13, 2015
- Letter from Kenyon Farrow, TAG's U.S. & Global Health Policy Director
- Message from Board President Barbara Hughes
- Ending the Epidemic Update
- HCV Report from the Front
The Fair Pricing Coalition (FPC) applauds the Wyden-Grassley US Senate bipartisan Sovaldi investigation spotlighting a greed-driven pricing strategy behind Gilead’s $1,000 per pill hepatitis C drug launch
December 3, 2015 – “This remarkable investigative report is an indictment against Gilead and the US drug pricing system which allows lifesaving drugs to be priced beyond what the market can reasonably bear,”
Webinar: Envisioning comprehensive HIV prevention service delivery in the US
Join Treatment Action Group and the HIV Prevention Justice Alliance for a webinar on Thursday, Dec. 17, 2 to 3:30 p.m. ET as we discuss the current state of the HIV prevention toolbox and an introduction to the HIV prevention continuum. Moderated by TAG's Jeremiah Johnson.
An Activist’s Guide to Regulatory Issues: Ensuring Fair Evaluation of and Access to Tuberculosis Treatment
December 2015 – This guide explains different regulatory processes and terms and offers examples of how to use a variety of regulatory mechanisms to improve access to treatment. The guide also encourages activists to advocate for effective, efficient, transparent regulatory systems.
Tuberculosis Research Funding Crisis Imperils Elimination Goal
November 30, 2015, Cape Town, South Africa – Worldwide funding for tuberculosis (TB) research fell $1.3 billion short of global targets in 2014, according to a report released today by Treatment Action Group (TAG). Total funding of US$674,036,492 in 2014 amounted to barely one-third of the US$2 billion experts estimate the world must spend on TB research and development (R&D) each year to eliminate TB. Alarmingly, funding for TB drug research fell by US$25 million compared with 2013. Overall, funding for TB R&D fell by US$12 million.
Symposium: Scale Up to Get Down to Zero TB Deaths, New Infections, and Suffering
In conjunction with the 2015 Union World Conference on Lung Health Conference
Friday, December 4, 2015
18h00 – 20h30
Southern Sun The Cullinan, Protea 1 & 2
1 Cullinan Street Cape Town Waterfront
Cape Town, South Africa 8001
TAG's Response to Sen. Cassidy Statements on AIDS Research Spending
November 19, 2015 – I would like to offer comments to correct the record on statements given by Senator Bill Cassidy (R-LA) at the October 7, 2015, hearing on the National Institutes of Health fiscal year 2016 budget. Several of his comments to the committee and NIH Director Francis Collins were incorrect or misleading. If his erroneous statements about AIDS research funding at the NIH are mistaken for fact, we will set a dangerous course for current and future research being conducted at the agency and undermine the prioritization process under way at the Office of AIDS Research (OAR).
TAG Response to the Release of the World Health Organization’s 2015 Global Tuberculosis Report
October 28, 2015 – Global leaders’ half-hearted response has enabled TB to overtake AIDS as the world’s leading cause of death from an infectious disease.
- In Defense of Stringency
By Tim Horn
- The 21st Century Cures Act’s “Pathway to Crisis” in Drug Safety
By Kenyon Farrow
- The FDA’s Concession Conundrum
By Lindsay McKenna and Erica Lessem
- The Challenge of Defining HIV Remission
By Richard Jefferys
- Improving Regulatory Systems to Address Global TB Drug Access Failures
By Erica Lessem
- PrEP: The Pathway to Global Access
By Scott Morgan
Leading Advocates and Organizations Call on Gilead to Price TAF Responsibly
September 21, 2015 – The Fair Pricing Coalition sent the letter to Gilead, with 115 organizational and 376 individual signatories.
ACT UP/New York and TAG to Host Town Hall Meeting to Discuss Drastic Cuts to City’s HIV Testing and STD Screening Programs
August 31, 2015, New York, New York – In response to disturbing trends in New York City’s response to the ongoing HIV and STD epidemics, ACT UP/New York and Treatment Action Group (TAG) will host a town hall meeting at the New York City LGBT Center on West 13th Street in Manhattan at 6:30 p.m. on September 1, 2015. ACT UP and TAG seek to push the de Blasio administration to mitigate the massive citywide reduction of sexual health services in recent years, including the March 2015 closure of the Chelsea STD Clinic.
Don’t Forget Treatment on World Hepatitis Day
July 28, 2015 – The prohibitive price of hepatitis C virus medications will result in needless deaths if we don’t act now
On World Hepatitis Day 2015, as the World Health Organization (WHO) emphasizes prevention, the International Treatment Preparedness Coalition (ITPC) and Treatment Action Group (TAG) urge pharmaceutical companies and the governments of middle-income countries (MICs) to act now to facilitate access to treatment for all people with hepatitis C virus (HCV), to avoid needless deaths from HCV complications and to prevent new infections.
2015 Pipeline Report
July 17, 2015 – HIV, HCV, and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development
Washington Blade Op-Ed: D.C. AIDS Plan Ambitious but Must Include Community
July 10, 2015 – By Kenyon Farrow – Could D.C. be the next place that declares a bold plan for ending the HIV epidemic in just a few years? New York Gov. Andrew Cuomo was the first governor to announce such an effort. Now it appears that Mayor Muriel Bowser wants to make this a priority in her first term. But while I applaud the mayor for taking on this ambitious (yet achievable) goal, she needs to make the community part of the process of conceiving, developing, and implementing this new plan.
Public Health Groups Sue FDA For Disclosure of Clinical Trial Data for Costly Hep C Drugs
June 25, 2015, New Haven, Connecticut – Treatment Action Group (TAG) and the Global Health Justice Partnership (GHJP) have filed a federal lawsuit to obtain access to the information that Gilead Sciences submitted to the FDA to obtain approval of two new—and extremely expensive—hepatitis C drugs, Sovaldi (sofosbuvir) and Harvoni (sofosvubir/ledipasvir). Hepatitis C affects at least 3 million people in the United States. Sovaldi and Harvoni significantly improve cure rates, but initial pricing was unprecedented: $84,000 and $94,500 for a 12-week course of treatment, respectively.
Toward Comprehensive HIV Prevention Service Delivery in the United States: An Action Plan
June 24, 2015 – An objective of the National HIV/AIDS Strategy (NHAS), released by the White House in July 2010, is to lower the annual number of new infections in the United States by 25 percent by the end of 2015. Yet it is unclear if we will succeed in meeting this arguably unambitious target: 36,400 estimated new infections in 2015, compared with the 48,600 new infections estimated for the baseline year of 2006.
NYTimes Op-Ed: Don’t Weaken the F.D.A.’s Drug Approval Process
By Gregg Gonsalves, Mark Harrington, and David A. Kessler
June 11, 2015 – During the early days of the AIDS epidemic in the 1980s, there were no effective treatments against H.I.V., the virus that causes the disease. Because of this, many thousands of people died lingering deaths. The desperation of those times led to the rise of an activist movement that took to the streets and pressed government officials to expedite research on drugs to treat AIDS.
2014 Annual Report
May 29, 2015 – Progress in the Fight Against HIV, HCV, and TB.
TAG’s Involvement in HIV Cure Research
May 19, 2015 – A brief overview of TAG’s advocacy role in the pursuit of an HIV cure.
Gilead: Stop Blocking Access to Hepatitis C Treatment
Thousands of activists urge company to change its policies on eve of shareholder meeting
May 5, 2015, New York, New York – On the eve of pharmaceutical company Gilead Sciences’ annual shareholder meeting, thousands of people who have hepatitis C virus (HCV) and HCV/HIV coinfection, with their allies and physicians, have demanded that Gilead change its policies that deny access to treatment for millions of people in developing countries.
Governor Releases Blueprint to End AIDS in New York State by 2020
April 29, 2015, New York, New York – Governor Cuomo formally accepted the long-awaited Blueprint to End AIDS at a public event on Wednesday, marking an important step towards fulfilling his commitment to end AIDS in New York State.
Governor Cuomo’s Plan to End AIDS Will Save Lives and Money
April 21, 2015 – TAG & Housing Works Report Shows Plan to End AIDS by 2020 Will Translate into $4.5 Billion in Net Medicaid Savings for NY State.
- On Targets and Timelines
With growing recognition that science and discovery have forged the tools necessary to effectively diagnose, treat, and, indeed, eliminate three of the world’s most lethal infectious diseases—HIV/AIDS, tuberculosis, and hepatitis C—there is a need for greater mobilization and strengthened accountability among all stakeholders.
- Ending the HIV Epidemic (ETE) in New York State
Not only is it the right thing to do for the health of New Yorkers, but a new analysis demonstrates that it is also cost-effective.
- Toward an Ambitious National HIV/AIDS Strategy
We won’t end HIV as an epidemic with anemic goals, delayed surveillance data, feeble support of state policies and resource needs, and an inadequate implementation science agenda.
- An HIV Cure and a Vaccine within the Next 15 Years?
Optimism is not without merit, but the science remains incredibly fragile.
- C U L8ter: Hepatitis C Eradication
Hepatitis C is now curable. Now all we need is surveillance to monitor it, global funding to fight it, and targets set to address it.
- TB R&D’s Shift to the Left
As the Bill & Melinda Gates Foundation realigns its TB vaccine strategy to focus on early-stage candidate development, equitable access priorities must also be established before large-scale trials are conducted.
Guiding Principles for Eliminating Disease-Specific Criminal Laws
February 27, 2015 – The Positive Justice Project is dedicated to eliminating disease-specific criminal laws that base liability on an individual’s health status rather than on the intent to harm another individual. We oppose the use of felony laws, and the associated lengthy terms of incarceration that treat health status as evidence of wrongful intent, and transmission of a treatable illness as equivalent to manslaughter, vehicular homicide, and other forms of assaults that pose immediate, lifethreatening harm to another.
150 HIV Organizations Urge Continuation of D:A:D Study
February 20, 2015 – HIV drugs are used in combinations, so it is right that the companies who make and sell these drugs collaborate on this study on long-term safety.
Activist Strategies for Increasing Access to HCV Treatment in Low- and Middle-Income Countries (English and Russian)
February 2, 2015 – This report presents a number of key strategies through real-world case studies and shows how strategies used to combat the AIDS epidemic can be—and have been—adapted to increase HCV treatment access. These strategies are introduced in three sections: Laying the groundwork through community organizing; overcoming the cost barriers to HCV treatment access; and collaborating with researchers to build your case for HCV treatment access.
Governor Cuomo’s Ending the Epidemic Task Force Completes Plan to End AIDS in NY State by 2020
– Activists, service providers, public health professionals hail governor’s leadership, call on legislators and local governments to join forces to end the epidemic –
January 13, 2015, Albany, New York. Today the Ending the Epidemic Task Force, convened by the New York State Department of Health (DOH) at the behest of Governor Andrew M. Cuomo, completed its comprehensive, rigorous, and unprecedented plan to end AIDS in New York State by 2020.